Effect of Troglitazone on Steady-State Pharmacokinetics of Digoxin
- 1 February 1998
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 38 (2) , 178-183
- https://doi.org/10.1002/j.1552-4604.1998.tb04408.x
Abstract
Twelve healthy subjects participated in a study to determine the effect of multiple doses of troglitazone on the steady‐state pharmacokinetics of digoxin. Subjects received digoxin 0.25 mg orally once daily on days 1 through 20 and 400 mg of troglitazone orally once daily on days 11 through 20. Serial plasma samples and 24‐hour urine samples collected before and after the doses on days 10 and 20 were analyzed for digoxin using a radioimmunoassay method. Eleven subjects completed the study. Administration of multiple oral doses of digoxin and troglitazone was well tolerated. Mean values for maximum concentration (Cmax), time to Cmax (tmax), and area under the concentration—time curve from 0 to 24 hours (AUC0–24) of digoxin on day 10 were similar to those on day 20. Mean day 10 digoxin values for minimum concentration (Cmin), apparent oral clearance (Cl/F), total urinary excretion from 0 to 24 hours (Ae0–24), and renal clearance (Clr) were also similar to corresponding values on day 20. Thus, concomitant administration of multiple‐dose troglitazone does not alter the steady‐state pharmacokinetics of digoxin.Keywords
This publication has 19 references indexed in Scilit:
- Lack of Effect of Type II Diabetes on the Pharmacokinetics of Troglitazone in a Multiple-Dose StudyThe Journal of Clinical Pharmacology, 1997
- Meta‐Analysis of Steady‐State Pharmacokinetics of Troglitazone and Its MetabolitesThe Journal of Clinical Pharmacology, 1997
- Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM SubjectsDiabetes Care, 1992
- Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDMDiabetes Care, 1991
- Pharmacokinetic Interactions with DigoxinClinical Pharmacokinetics, 1988
- A Steady‐State Evaluation of the Effects of Propantheline Bromide and Cholestyramine on the Bioavailability of Digoxin When Administered as Tablets or CapsulesThe Journal of Clinical Pharmacology, 1985
- Clinical Pharmacokinetics of Digoxin 1980Clinical Pharmacokinetics, 1980
- Influence of Kaolin–Pectin Suspension on Digoxin BioavailabilityJournal of Pharmaceutical Sciences, 1978
- Decreased bioavailability of digoxin due to hypocholesterolemic interventions.Circulation, 1978
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976